Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,518 questions in 135 reviews · Infectious Diseases

current versions

No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Intervention NR Peripheral health centre with a prior probability of disease of 40% · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	6 studies · 1468 participants	High
Intervention NR Referral centre with a prior probability of disease of 60% · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	6 studies · 1468 participants	High
Intervention NR CI: confidence interval · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Peripheral health centre with a prior probability of disease of 40% · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	9 studies · 1692 participants	High
Intervention NR Referral centre with a prior probability of disease of 60% · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	9 studies · 1692 participants	High
Intervention NR CI: confidence interval · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Peripheral health centre with a prior probability of disease of 40% · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	6 studies · 1374 participants	High
Intervention NR Referral centre with a prior probability of disease of 60% · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	6 studies · 1374 participants	High
Intervention NR CI: confidence interval · Patients suspected to have visceral leishmaniasis disease 1 Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease (2014) · Cochrane	no estimate extracted	NR	No studies
Pre‐referral rectal artesunate vs placebo All cause mortality · Children and adults with severe malaria Pre‐referral rectal artesunate for severe malaria (2014) · Cochrane	RR 0.74 [0.59, 0.93]	1 study · 8050 participants	Moderate
Pre‐referral rectal artesunate vs placebo Neurodisability · Children and adults with severe malaria Pre‐referral rectal artesunate for severe malaria (2014) · Cochrane	RR 0.68 [0.35, 1.3]	1 study · 17280 participants	Low
Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine Treatment failure Day 28 · Patients with uncomplicated P. falciparum malaria Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria (2014) · Cochrane	RR 0.34 [0.3, 0.39]	9 studies · 6200 participants	High
Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine Treatment failure Day 63 · Patients with uncomplicated P. falciparum malaria Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria (2014) · Cochrane	RR 0.71 [0.65, 0.78]	2 studies · 3200 participants	High
Intervention NR All‐cause mortality · patients with managing pulmonary tuberculosis Adjunctive steroid therapy for managing pulmonary tuberculosis (2014) · Cochrane	RR 0.77 [0.51, 1.15]	18 studies · 3815 participants	Low
Intervention NR Sputum Conversion by 2 months · patients with managing pulmonary tuberculosis Adjunctive steroid therapy for managing pulmonary tuberculosis (2014) · Cochrane	RR 1.1 [1.03, 1.17]	11 studies · 1475 participants	Low
Intervention NR Sputum conversion at 6 months · patients with managing pulmonary tuberculosis Adjunctive steroid therapy for managing pulmonary tuberculosis (2014) · Cochrane	RR 1.01 [0.97, 1.05]	8 studies · 875 participants	Moderate
Intervention NR Clinical Improvement at 1 month · patients with managing pulmonary tuberculosis Adjunctive steroid therapy for managing pulmonary tuberculosis (2014) · Cochrane	RR 1.16 [1.09, 1.24]	5 studies · 497 participants	Very low
Intervention NR Parasitological failure at 1 month · People with S. mansoni infection Drugs for treating Schistosoma mansoni infection (2013) · Cochrane	RR 3.13 [1.03, 9.53]	2 studies · 414 participants	Moderate
Intervention NR Parasitological failure at 1 month · People with S. mansoni infection Drugs for treating Schistosoma mansoni infection (2013) · Cochrane	RR 8.74 [3.74, 20.43]	2 studies · 82 participants	Moderate
Oxamniquine 40 mg/kg vs praziquantel 40 mg/kg Parasitological failure at 1 month · People with S. mansoni infection Drugs for treating Schistosoma mansoni infection (2013) · Cochrane	RR 0.4 [0.13, 1.22]	1 study · 33 participants	Very low
Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) vs praziquantel (40 mg/kg) alone Parasitological failure at 1 month · People with S. mansoni infection Drugs for treating Schistosoma mansoni infection (2013) · Cochrane	RR 0.62 [0.35, 1.09]	1 study · 75 participants	Very low
Primaquine five days vs 14 days P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	RR 10.05 [2.82, 35.86]	2 studies · 186 participants	Moderate
Primaquine (weekly for eight weeks) vs daily primaquine P. vivax parasitaemia detected > 30 days after starting primaquine · Children and adults with blood smear positive P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	RR 2.97 [0.34, 25.87]	1 study · 129 participants	Very low
Primaquine (weekly for eight weeks) vs daily primaquine Serious adverse events · Children and adults with blood smear positive P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	1 study · 129 participants	Ungraded
Primaquine (weekly for eight weeks) vs daily primaquine Adverse events · Children and adults with blood smear positive P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	1 study · 129 participants	Ungraded
Intervention NR P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	RR 0.98 [0.73, 1.3]	4 studies · 2213 participants	High
Intervention NR Serious adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	4 studies · 2213 participants	Ungraded
Intervention NR Other adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	4 studies · 2213 participants	Ungraded
Intervention NR P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	RR 0.6 [0.48, 0.75]	10 studies · 1740 participants	High
Intervention NR Serious adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	10 studies · 1740 participants	Ungraded
Intervention NR Other adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	10 studies · 1740 participants	Ungraded
Primaquine five days vs 14 days Serious adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	2 studies · 186 participants	Ungraded
Primaquine five days vs 14 days Other adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	2 studies · 186 participants	Ungraded
Primaquine three days vs 14 days P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	RR 3.18 [2.1, 4.81]	2 studies · 262 participants	Moderate
Primaquine three days vs 14 days Serious adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	2 studies · 262 participants	Ungraded
Primaquine three days vs 14 days Other adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	2 studies · 262 participants	Ungraded
Primaquine seven days vs 14 days P. vivax parasitaemia detected > 30 days after starting primaquine · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	RR 2.24 [1.24, 4.03]	1 study · 126 participants	Low
Primaquine seven days vs 14 days Severe adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	1 study · 126 participants	Ungraded
Primaquine seven days vs 14 days Other adverse events · People with P. vivax malaria1 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (2013) · Cochrane	no estimate extracted	1 study · 126 participants	Ungraded
Fluoroquinolone plus standard regimen vs standard regimen alone Treatment failure · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen Death from any cause · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	RR 0.52 [0.21, 1.32]	3 studies · 723 participants	Very low
Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen TB‐related death · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	RR 0.33 [0.01, 8.07]	1 study · 170 participants	Very low
Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen Sputum culture conversion at 8 weeks · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	RR 1.07 [0.97, 1.19]	3 studies · 723 participants	Very low
Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen Serious adverse events · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	RR 0.93 [0.53, 1.62]	3 studies · 723 participants	Very low
Fluoroquinolone substitution for ethambutol in a standard six month regimen vs standard regimen One or more adverse events · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen Treatment failure · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen Relapse · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen Death from any cause · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	RR 0.75 [0.17, 3.3]	1 study · 433 participants	Low
Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen TB‐related death · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	RR 2 [0.18, 21.84]	1 study · 433 participants	Low
Fluoroquinolone substitution for isoniazid in a standard six month regimen vs standard regimen Sputum culture conversion at 8 weeks · Patients with presumed drug‐sensitive TB Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive) (2013) · Cochrane	RR 1.1 [0.91, 1.33]	1 study · 433 participants	Low